Measurable Residual Disease for ALL by Flow Cytometry (Accredited)

 

The measurement of Measurable Residual Disease (MRD) populations is often performed following treatment for leukaemic disorders. The levels of MRD are used as a predictive factor for relapse and as an indicator for patients entering remission. As such the measurement of MRD can have a direct effect on the treatment regimen of a patient.

 

This programme issues stabilised whole blood into which has been spiked some stabilised B-ALL material. Laboratories are required to determine the level of measurable residual disease by flow cytometry, please note this programme is not suitable for the measurement of MRD by molecular methods.

 

The programme issues a presentation sample together with 2 follow up samples. Please note that the presentation sample will not contain the expected level of disease seen in a typical clinical scenario. The 2 follow up samples are manufactured from the same B-ALL case and are designed to represent different stages post treatment to assess the ability of a centre to detect B-ALL leukaemic cells at minimal residual disease levels within a background of stabilised normal whole blood. Laboratories are requested to report the percentage of residual leukaemic cells in the 2 follow up samples as a percentage of the total leucocytes.

 

Three samples are issued per trial and this programme issues samples a minimum of 2 times per annum and a maximum of 4.

 

Trials for this programme are live/open for a minimum of 3 weeks.

Please Note: Trials issued/closing in August or December are extended by 1 week.

An automated email is sent 2 days prior to the trial closing, to any participant that has not returned results, warning them of the trial closure date. 

 

***NEW IN 2023-2024*** 

Following the successful redesign of the Measurable Residual Disease (MRD) for Plasma Cell Myeloma by Flow Cytometry programme in 2022-2023, we will roll out these changes out to the Measurable Residual Disease for ALL by Flow Cytometry Accredited) programme in 2023-2024.

 

In addition, to the standard 'wet' exercises, Educational Electronic Exercises will be included in this programme in 2023-2024. These exercises are to determine interpersonal differences between laboratory scientists when analysing standardised anonymised data files to help develop and support individual competencies in the analysis of acquired data. 

 

No activities in relation to this EQA programme are subcontracted.

 

To register for this programme, please click here.

Example Measurable Residual Disease for ALL by Flow Cytometry Report
To view the annotations on this report, please download the PDF and view in a PDF reader such as Adobe Acrobat.
MRD ALL 232402 annotated.pdf
Adobe Acrobat document [1.4 MB]
Measurable Residual Disease for ALL by Flow Cytometry Performance Monitoring System
Measurable Residual Disease for ALL by F[...]
Adobe Acrobat document [90.4 KB]
MRD ALL 242501 Coversheet
MRD ALL 242501.pdf
Adobe Acrobat document [260.3 KB]
Changes to MRD-ALL data entry pages
Changes to MRD-ALL data entry pages.pdf
Adobe Acrobat document [797.7 KB]
Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube

Disclaimer

Last updated 16/05/2024 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.


Please click here for our privacy policy.


The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).